CLDN10 is Associated with Papillary Thyroid Cancer Progression

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Thyroid cancer incidence remains high globally.
• Claudins, involved in cell-cell junctions, are implicated as diagnostic markers in various cancers.
• Claudin-10 (CLDN10) is overexpressed in several cancers, but its role in papillary thyroid cancer (PTC) is not well understood.

Purpose of the Study:

• To investigate the expression, correlation, and functional role of CLDN10 in papillary thyroid cancer (PTC).

Main Methods:

• Quantitative real-time polymerase chain reaction (qRT-PCR) to measure CLDN10 expression in PTC tissues.
• Analysis of TCGA (The Cancer Genome Atlas) cohort data for CLDN10 expression correlations.
• Kaplan-Meier survival analysis.
• In vitro experiments using PTC cell lines to assess CLDN10's functional impact.

Main Results:

• CLDN10 expression was significantly higher in PTC tissues compared to normal tissues.
• High CLDN10 expression correlated with lymph node metastasis, patient age, and histological type in TCGA data.
• Elevated CLDN10 levels were associated with poorer overall survival in PTC patients.
• In vitro studies demonstrated that CLDN10 promotes proliferation, migration, and invasion in PTC cell lines.

Conclusions:

• CLDN10 functions as an oncogene in papillary thyroid cancer (PTC).
• Its high expression facilitates tumor growth, metastasis, and invasion.
• CLDN10 represents a potential diagnostic marker and therapeutic target for PTC.